PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2015

Angiotensin-converting enzyme inhibition attenuates lipopolysaccharide-induced lung injury by regulating the balance between angiotensin-converting enzyme and angiotensin-converting enzyme 2 and inhibiting mitogen-activated protein kinase activation.

Rat / Endotoxin/LPS

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 25768373 ↗2015Reported benefit

Angiotensin-converting enzyme inhibition attenuates lipopolysaccharide-induced lung injury by regulating the balance between angiotensin-converting enzyme and angiotensin-converting enzyme 2 and inhibiting mitogen-activated protein kinase activation.

RatEndotoxin/LPSSprague-DawleyMaleIntraperitoneal in vivo50 mg/kg in vivo; 10 mol/mL in vitro as printed in the sour…30 min before lipopolysaccharide administration

Model: Lipopolysaccharide-induced acute lung injury (7.5 mg/kg lipopolysaccharide intravenously); rat pulmonary microvascular endothelial cells stimulated with lipopolysaccharide in vitro

Captopril pretreatment attenuated lung pathology, reduced tumour necrosis factor-alpha and interleukin-6, lowered the angiotensin II to angiotensin-1-7 ratio and reduced the ACE to ACE2 ratio from 7.07 to 1.71 in vivo and 5.18 to 1.52 in vitro, with inhibition of p38 MAPK, ERK1/2 and JNK phosphoryl…

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.